Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Investor Presentation (January 2025)
28 slides from Perspective Therapeutics's investor presentation, Jan 24, 2025
Slide 1: Investor Call ASCO-GI 2025 Presentation
Investor Call ASCO-GI 2025 Presentation January 24, 2025 NYSE AMERICAN: CATX
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,”
Slide 3: Developing the Next Generation of Targeted Therapies
Developing the Next Generation of Targeted Therapies Robust Manufacturing Infrastructure Radioisotope supply strengthened by integrated supply chain Patient coverage via distributed manufacturing infrastructure Ready-to-administer products provided to treatment sites on day of scheduled treatment In
Slide 4: Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window
Perspective’s Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window Perspective Therapeutics’ Platform Optimized peptides Highly specific for tumor cell receptors Rapid clearance from blood to reduce off-target effects Ideal isotope Double-stranded breaks cell death Reduced off-t
Slide 5: Broad Proprietary Pipeline
Program (Target) Target Disease Candidate evaluation Human Clinical Imaging Phase 1/2 Registration Enabling Study Status VMT01/02 (MC1R) Melanoma (MC1R imaging & therapy) Next cohort is open for enrollment Open for enrollment VMT-⍺-NET (SSTR2) Neuroendocrine tumors Cohort 2: enrolling Cohort 3: Pend
Slide 6: Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment
Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Bars representative of relative size of the addressable market (both current and potential future) but not to sc
Slide 7: Neuroendocrine Tumors: VMT-⍺-NET
Neuroendocrine Tumors: VMT-⍺-NET Targeting the somatostatin receptor to treat rare neuroendocrine-type cancers
Slide 8: Neuroendocrine Tumors: VMT-⍺-NET
Whole body SPECT scan of NETs patient imaged with [203Pb]VMT-𝛼-NET Neuroendocrine Tumors: VMT-⍺-NET Targeting the somatostatin receptor to treat neuroendocrine and other cancers Neuroendocrine cells are specialized cells that secrete hormones and other bioactive substances Most neuroendocrine…
Slide 9: NET Trials 177Lu-DOTATATE
NET Trials 177Lu-DOTATATE Study NETTER-1 (1) (2) RCT; randomized 2:1 N = 229 Dose Level (administered) 4 x Q8W | 200 mCi Patient Population SSTR2+, GEP-NETs Prior PRRT 0% Median time from dx 3.8 years Performance Status Karnofsky Performance Scale Median was 90 Histology Well differentiated G1 (66%)
Slide 10: Interim safety and efficacy data of [212Pb]VMT-α-NET in NETs
Interim safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs) Richard Wahl, Lowell Anthony, Lilja Solnes, Samuel Mehr, Lucia Baratto, Alaa Hanna, Wenjing Yang, Stephen Keefe, Thorvardur Halfdanarson
Slide 11: Disclosures for Dr. Richard Wahl and FDA Status
Disclosures for Dr. Richard Wahl and FDA Status Abdera: consultant Molecular Targeting Technologies, Inc.: consultant, stock options Siemens Healthineers: consultant Voximetry: consultant, stock options Techspert: consultant Clarity Pharmaceuticals: stockholder Perspective Therapeutics: consultant,
Slide 12: Trial Parameters
PRRT = peptide receptor radionuclide therapy | mTPI-2: Modified toxicity probability index For additional details regarding trial parameters, including criteria for patient selection, please refer to slide 68 or https://clinicaltrials.gov/study/NCT05636618. Trial Parameters Dose-finding Population K
Slide 13: Patient Characteristics
Patient Characteristics (all patients as treated) Wahl RL et al, Presentation at ASCO-GI 2025. Full presentation available here. Data cut off date January 10, 2025 All Treated (N = 9 ) Age (years) Median 63 Range 37,78 Sex, n (%) Female 4 (44) Male 5 (56) Race, n (%) White 8 (89) Asian 1 (11) Weight
Slide 14: Safety Findings Unchanged
Safety Findings Unchanged Wahl RL et al, Presentation at ASCO-GI 2025. Full presentation available here. Data cut off date January 10, 2025 No DLTs were observed in either cohort No grade 4, grade 5 or serious AEs were observed No decline in renal function was observed Hematologic AEs were few in nu
Slide 15: [212Pb]VMT-α-NET Was Well Tolerated
[212Pb]VMT-α-NET Was Well Tolerated *The date of one of two episodes of dizziness reported at NANETS was revised to occur >8 weeks following last treatment and therefore no longer meets the definition for treatment-emergent. Wahl RL et al, Presentation at ASCO-GI 2025. Full presentation available he
Slide 16: No Decline in Renal Function Observed
No Decline in Renal Function Observed Wahl RL et al, Presentation at ASCO-GI 2025. Full presentation available here. Data cut off date January 10, 2025 Most recent eGFR versus baseline Most recent on-study eGFR [212Pb]VMT-α-NET 2.5 mCi (92.5 MBq) [212Pb]VMT-α-NET 5.0 mCi (185 MBq) eGFR eligibility c
Slide 17: Previously Presented at NANETS 2024: Preliminary response assessment
Previously Presented at NANETS 2024: Preliminary response assessment by RECIST v1.1 * The full sets of scans following cycle 4 are not yet available to the study team for five patients. Note: Patient 109-103 experienced progressive disease by unambiguous progression of non-target lesions. Wahl RL et
Slide 18: Updated at ASCO-GI 2025: Anti-Tumor Activity
Updated at ASCO-GI 2025: Anti-Tumor Activity Note: Patient 109-103 experienced progressive disease by unambiguous progression of non-target lesions. Wahl RL et al, Presentation at ASCO-GI 2025. Full presentation available here. Data cut off date January 10, 2025 Preliminary response assessment by RE
Slide 19: Previously Presented at NANETS 2024: Disease Control Durability
Previously Presented at NANETS 2024: Preliminary Assessment of Disease Control Durability Wahl RL et al, Presentation at NANETS 2024. Full presentation available here. Data cut off date October 31, 2024 NANETS 2024
Slide 20: Updated at ASCO-GI 2025: Eight of Nine Patients Remain on Study
Updated at ASCO-GI 2025: Eight of Nine Patients Remain on Study Note: Lighter portions of each line signify transition of the patient to follow-up period (begins 8 weeks after last dose). Response for Patient 103-104 has been confirmed; other responses subject to confirmation. Patient 102-103 had a
Slide 21: Previously Presented at NANETS 2024: Kinetics of Treatment Response
Previously Presented at NANETS 2024: Kinetics of Treatment Response The full sets of scans following cycle 4 are not yet available to the study team for five patients. Notes: Patients had progressive disease prior to enrollment on study, and patient 109-103 experienced progressive disease by unambig
Slide 22: Updated at ASCO-GI 2025: Signal of Sustained Anti-Tumor Activity
Updated at ASCO-GI 2025: Signal of Sustained Anti-Tumor Activity Notes: 1 patients had progressive disease prior to enrollment on study, and patient 109-103 experienced progressive disease by unambiguous progression of non-target lesions Patient 102-103 had a longer treatment period due to delay in
Slide 23: Patient with PR after [212Pb]VMT-α-NET
Patient with PR after [212Pb]VMT-α-NET Wahl RL et al, Presentation at ASCO-GI 2025. Full presentation available here. Data cut off date January 10, 2025 Contrast-Enhanced CT and DOTATATE PET scans show partial response Baseline After cycle 2 After cycle 1 After cycle 3 After cycle 4 Follow up week 3
Slide 24: Next steps and concluding remarks
Next steps and concluding remarks
Slide 25: Conclusion & Next Steps
[212Pb]VMT-α-NET was well-tolerated1 1Wahl RL et al, Presentation at ASCO-GI 2025. Full presentation available here. Data cut off date January 10, 2025 No DLTs No grade 4, grade 5 AEs or SAEs No decline in renal function Hematologic AEs were low in number and low grade No treatment discontinuations
Slide 26: Q & A
Q & A
Slide 27: Backup slides
Backup slides
Slide 28: Abbreviations
Abbreviations AE: adverse event APC: antigen-presenting cell ASCO-GI: ASCO Gastrointestinal Cancers Symposium DAMPs: damage-associated molecular patterns DLT: dose limiting toxicities dsDNA: double-stranded DNA EANM: European Association of Nuclear Medicine eGFR: estimated glomerular filtration rate
Perspective Therapeutics — Investor Presentation (January 2025) on 6ix